CSI Market
Sign In | Register

Corcept Therapeutics Inc (CORT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CORT quarterly Cash Flow →
The data below summarizes Corcept Therapeutics Inc's cash flow activity from Dec 31 2021 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income99.65
Depreciation & amortization1.15
Amortization of Other Assets0.00
Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-7.48
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation84.50
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Settlement Of Liquidated Damages In Stock-
Expense Related To Stock Issued In Conjunction With License Agreement-
Expense Related To Stock Issued Below Fair Value-
Accretion Expense Income-
Accretion Of Interest Income Expense-
Operating Lease Right Of Use Asset Amortization-
Interest Income Debt Securities Available For Sale Operating-
Investment Income Amortization Of Discount-
Investment Income Amortization Of Premium-
Operating Lease Right Of Use Asset Amortization Expense0.74
Increase Decrease In Insurance Recovery Receivable-
Increase Decrease In Accrued Research And Development Expenses0.09
Increase Decrease In Accrued Clinical Expenses-
Increase Decrease In Operating Lease Liability-0.83
Income taxes-36.45
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-5.81
Increase (Decrease) in Accounts Payable25.07
Increase (Decrease) in Other Accrued Liabilities3.93
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-18.92
Other Working Capital1.46
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-5.10
Discontinued operations0.00
Net Cash flow from Operating Activities142.00
Investing Activities
Capital Expenditures-0.21
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities389.58
Payments to Acquire Marketable Securities-319.61
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities69.76
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-147.43
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-200.61
Proceeds From Issuance Of Common Stock And Warrants Including Collection Of Notes Receivable Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents127.67
Payments For Repurchase Of Common Stock In Connection With Tender Offer-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-220.37
Effect of exchange rate on cash flow1.44
Discontinued operations0.00
Free Cash Flow141.79
Total Cash Flow-7.17
4 historic quarters locked

Sign in to unlock the full Corcept Therapeutics Inc cash flow history.

Sign In Create Free Account

About Corcept Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 24, 2026
  • Source: cort-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-011091

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License